Illumina, Inc. $ILMN Holdings Lowered by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 310,751 shares of the life sciences company’s stock after selling 13,928 shares during the period. Illumina comprises approximately 1.0% of Douglas Lane & Associates LLC’s portfolio, making the stock its 28th largest holding. Douglas Lane & Associates LLC’s holdings in Illumina were worth $85,046,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in ILMN. BlackRock Inc. acquired a new position in shares of Illumina in the second quarter valued at about $3,374,423,000. Primecap Management Co. CA acquired a new stake in Illumina during the second quarter valued at $617,981,000. Jupiter Topco LLC acquired a new position in Illumina in the 2nd quarter worth about $358,652,000. WCM Investment Management LLC lifted its position in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Illumina in the 2nd quarter worth about $293,846,000. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on ILMN. Weiss Ratings restated a “hold (c)” rating on shares of Illumina in a research report on Monday, August 31st. Guggenheim upped their price objective on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a research report on Wednesday, August 5th. Stifel Nicolaus upped their price target on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Citigroup upped their price objective on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a report on Monday, August 3rd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $222.19.

Illumina Stock Up 3.0%

ILMN stock traded up $8.06 during trading hours on Friday, hitting $272.63. The company’s stock had a trading volume of 714,776 shares, compared to its average volume of 2,169,341. The company has a market capitalization of $41.17 billion, a PE ratio of 50.76, a price-to-earnings-growth ratio of 3.79 and a beta of 1.41. The stock has a 50 day moving average price of $225.72 and a two-hundred day moving average price of $180.21. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $309.35. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the business earned $1.19 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 2,061,850 shares of company stock worth $436,479,102 over the last quarter. Company insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.